Okomera

Okomera is an innovative biotech company building a next-generation, automated platform for organoid-based drug discovery and personalized medicine. Its core technology leverages microfluidic chips to generate and screen thousands of patient-derived 3D tumor spheroids against hundreds of drug conditions (chemotherapy, immunotherapy, cell therapy) in a highly miniaturized and automated workflow, significantly reducing sample requirements and turnaround time compared to conventional methods. By combining high-throughput biology with AI-driven analysis, Okomera aims to improve the predictability of preclinical studies and enable scalable, data-rich applications such as CRISPR screening, T-cell potency testing, and combinatorial drug discovery. The company is positioned as a platform technology provider serving the broader oncology research and drug development market.

Ocentra platform: An automated, high-throughput microfluidic system for generating and screening patient-derived 3D organoids (microtumors). It uses droplet-based microfluidics to culture miniaturized spheroids from very few cells, enabling multiplexed testing of hundreds of drug/immune co-culture conditions, integrated with an AI-driven analysis suite.

Okomera competes in the organoid and complex 3D cell culture market against companies like Crown Bioscience (JSR Life Sciences), Hubrecht Organoid Technology, and Emulate. Its key differentiator is the combination of high-throughput automation, extreme miniaturization, and microfluidics-on-chip. It also faces competition from broader preclinical CROs and diagnostic companies developing functional precision oncology assays.